SlideShare a Scribd company logo
Biologicals framework updates
Tony Manderson
Head, Cell & Tissue Therapies Unit
Therapeutic Goods Administration
September 2017
Overview
• Biologicals framework
• Current regulatory status
• Challenges
• Changes
– General
– Excluded Goods Order
– MMDR changes
1
Medicines and blood products
• prescription medicines
• over-the-counter medicines
• complementary medicines
• blood, blood components and plasma derivatives
Medical devices
• implants (artificial hips, breast implants)
• in-vitro diagnostics (pregnancy tests, blood glucose monitors)
• low risk medical devices (bandages, tongue depressors, condoms)
Biologicals
• human stem cells
• tissue-based products (skin and bone)
• cell-based products
2
What are biologicals?
In Australia, ‘biologicals’is the name for cell and
tissue therapy products:
• Comprises, contains or is derived from human cells
or tissues
• Represented in any way to be for therapeutic use
• Live animal cells, tissues and organs
• Framework was introduced on 31 May 2011 to provide a
legislative basis for the regulation of these products.
• It applies different levels of regulation to products
based on the risks associated with their use, and was
designed to accommodate emerging technologies. 3
The Australian biologicals framework
Regulated as
biologicals
Tissue-based products
(skin, bone, ocular,
cardiovascular)
Cell-based products (T cell
therapies, human stem cells)
Combined cell and tissue
products (collagen matrices
for localised cell delivery)
Not regulated by TGA*
Fresh viable organs
Assisted reproductive
technologies
(in vitro fertilisation)
Fresh haematopoietic
progenitor cells
(bone marrow transplants)
Cells and tissues made by a
medical practitioner for a
single patient under the care
of that medical practitioner
*It is not practical to regulate these
products. There are appropriate checks in
place because of professional practice.
Regulated, but not
as biologicals^
Viable animal tissue products
(xenotransplantation)
Biological prescription
medicines (vaccines, plasma
derivatives)
Labile blood and blood
components
Haematopoietic progenitor
cells (non-fresh transplants)
^These are regulated as either
medicines or medical devices
4
Non-viable animal tissue
products
4
Biologicals are grouped into classes
Examples:
Acellular skin
for wound
covering
Mesenchymal
stem cell for
treatment of
graft-versus-
host disease
Demineralised
bone mixed with
carrier
Dermal
fibroblasts
transformed for
skeletal muscle
repair in primary
myopathy
Genetically-
modified T cells
used to treat
specific virus
infections
Class 2 Class 3 Class 3 Class 4 Class 4
11
Current approvals
• Class 2
– All domestic tissue banks (eye, skin, musculoskeletal,
cardiovascular)
– Some overseas tissue e.g. acellular skin
• Class 3
– Ortho-ACI
– Demineralised bone matrix - mixed with carrier (overseas)
• Class 4
– Approved 4 CTX applications for CAR T cells and parthenogenically-
derived stem cells
6
Challenges
• Clinical trials
− Focus on quality aspects that relate to safety e.g. donor selection and
testing, control over manufacturing, control of vector, insertional
mutagenesis
− No review of potency
− Control and quality of critical materials
• Product registration
− Poor product characterisation – defines the design of the
manufacturing process
− Development of surrogate potency assays
− Scale-up, changes to the manufacturing process (comparability)
7
Recent and proposed changes
• Live animal cell & tissue therapies now under the biologicals framework
− Number in clinical trial development e.g. encapsulated porcine islets
− Non-living animal tissue still to be regulated as Medical Devices
• Update to TGO 75 – Standards for cord blood-derived HPC
• Update to TGO 81 – Standards for blood & blood components (2018)
• Update to the Australian Regulatory Guidelines for Biologicals
− Major structural update to guidance
− Revision of content and expansion
− Change to dossier structure – CTD
• Biovigilance and RMP guidance
8
Review of the Therapeutic Goods (Excluded Goods)
Order No.1 of 2011
• Autologous cells and tissues (Medical practice)
– collected under the care of a medical practitioner, and
– manufactured for treatment of a single indication, and
– in a single course of treatment of that patient by the same
medical practitioner, or by a person under their supervision
– Other autologous uses are not exempt in Australia
• Under review due to concerns raised by stakeholders
• Two rounds of public consultation (2015 & 2016)
• Recommendations shortly to be provided to the Minister
• Guidance is being prepared
• Communication plan 9
Medicines and Medical Devices review (MMDR)
• Biologicals were not within the scope of the review
• Where possible the legislative changes and new pathways will also be rolled out for biologicals
• MMDR updates:
• Changes to advertising powers and enhanced post-market monitoring capability
• Orphan drug program – not for biologicals
• Expedited pathways - comparable overseas reports, priority review, provisional approval
• Self-assessable notifications, electronic forms for variations
• Support and advice for SME’s
• SAS C process
10
MMDR expedited pathways
• To facilitate earlier access to medicines that address unmet clinical needs for Australians, without
compromising standards for safety, efficacy and quality.
• Two new ‘expedited’ pathways for prescription medicines based on the government response to
the recommendations of the MMDR review:
– Priority Review of a complete data dossier within a reduced timeframe in certain
circumstances
Implemented 1 July 2017
– Provisional Approval on the basis of early data on safety and efficacy, where the immediate
availability of the medicine outweighs the risk that more data is required
Under development, planned for first quarter of 2018
11
Expedited pathways: Eligibility criteria
• New prescription medicine or new indication
• High level eligibility criteria for Priority Review and Provisional Approval
 Serious condition; and
 Major therapeutic advance; and
 Positive comparison against existing therapeutic goods
Priority Review based on ‘substantial evidence’
Provisional Approval based on ‘promising evidence from early clinical data’
• Sponsors may apply for the Orphan designation prior to or simultaneously with a Priority
Review or Provisional Approval designation application
12
Comparable overseas regulator
• Expedited review process where a report from a Comparable Overseas Regulator
(COR) is available
• To replace the current Category 2 process
• Consulted on the COR criteria and TGA considerations
• The report would be submitted along with a complete dossier, some Australian-specific
information and additional evidence, as required.
• Further targeted consultation on conditions and proposed pathways to be consulted with
industry
13
Provisional approval
Provisional Approval implementation scheduled for first quarter of 2018
(subject to legislative amendments)
• Provisional registration of goods in the initial absence of full clinical data on safety and
efficacy
• Granted for specified time periods (2 years + up to 2 extensions of 1-2 years each)
• Sponsors required to collect and submit further clinical data to demonstrate efficacy
and safety for full registration
• Enhanced post-market monitoring and surveillance
• Subject to the provision of clear advice to consumers and healthcare professionals and
any other conditions imposed by the TGA
10
Risk-based approach to minor variations -
notifications
All registered medicines:
• OTC
• Registered complementary medicines
• Prescription (chemical and biological medicines)
• Biologicals (human cells and tissues)
Staged
implementation
15
New electronic form for prescription medicines
minor variations
One-stop shop
• Consolidating six PDF forms into one electronic form
• Reduced time and effort in making applications
• Allows a real-time view of ARTG entries
• More efficient processing of requests
Launch
• 18 sponsors were involved in testing
• Progressive soft launch during July
• Full launch 25 July 2017
• Paper forms will be turned off as an option by legal
instrument in the near future.
Prescription Medicines Reforms
16
Notifications for biologicals
17
SME Assist
Guidance materials should be easily accessed and understood
by a range of audiences, including small and medium
enterprises (SMEs)
• Launched Friday, 9 June 2017 at the Translational Research
Institute, Brisbane by the Hon Greg Hunt, Minister for Health
and Sport.
 Targets the needs of SMEs and R&D groups
 Assists them to meet requirements for local and
international markets
 Provides Australian consumers with earlier access to
innovative therapeutic goods
SME Assist – 5 key components
1) SME Assist web page
 Articles covering basics, market
authorisation, when to engage with the
TGA
 Targeted at SMEs and organisations that
have not previously interacted with TGA
2) Education and training
 Activities and programs (face-to-face
workshops, webinars)
 Videos and presentations
SME Assist – 5 key components
3) Interactive tools
 Decision trees to better understand therapeutic goods regulation
relevant to their product
− Is my product a therapeutic good?
− What classification is my biological?
4) Triage and improved phone/email support
 To provide more tailored and efficient assistance to SMEs
5) Improved data capture
 To better identify SMEs and sponsors and direct their queries
 Subscription list
Access to unapproved biologicals
Special Access Scheme (SAS) Category C
• Certain unapproved therapeutic goods with an established
history of use to be supplied
• Goods which can be notified under Category C are listed in
legislative instruments which specify:
− the specific therapeutic good
− the approved indication(s) for use and
− the health practitioner authorised to supply
• Prior approval is not required from
• Copy of the completed Category C form must be sent to TGA
within 28 days of the therapeutic goods being supplied
21
TGA Presentation: Biologicals framework updates

More Related Content

PDF
Presentation: Updates from the Therapeutic Goods Administration
PDF
TGA Presentation: GMP Clearance Information Session,5-7 September 2017
PPTX
Notifications to prescription medicines
PPTX
GPs’ role in quality use of medicines in Australia
PPTX
The ACSS Consortium And The Generic Medicines Work-Sharing Trial
PPTX
Presentaion: Updates to Good Manufacturing Practices
PPTX
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
PPTX
Presentation: Conformity assessment evidence
Presentation: Updates from the Therapeutic Goods Administration
TGA Presentation: GMP Clearance Information Session,5-7 September 2017
Notifications to prescription medicines
GPs’ role in quality use of medicines in Australia
The ACSS Consortium And The Generic Medicines Work-Sharing Trial
Presentaion: Updates to Good Manufacturing Practices
Presentation: Revision of the Uniform Recall Procedure for Therapeutic Goods ...
Presentation: Conformity assessment evidence

What's hot (20)

PPTX
Presentation: GMP clearance requirements for medicines manufactured overseas
PPTX
Presentation: Spotlight on prescription medicines reforms
PPTX
Presentation: Prescription Medicines Reforms
PPTX
TGA presentation: Codeine Industry Forum - Regulatory options for up-scheduling
PPTX
Presentation: The Australian Pharmacovigilance Inspection Program
PPTX
Presentation: Pharmacovigilance: The Australian landscape
PPTX
Presentation: Supply and distribution of therapeutic goods
PPTX
Presentation: Earlier access to medicines and medical technologies and the MMDR
PPTX
Updates to Good Manufacturing Practices - Recent, current and future changes
PDF
Spotlight on MMDR Further Reviews and Advertising Reforms
PDF
Presentation: The Australian Pharmacovigilance Inspection Program (PVIP)
PPTX
The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016
PPTX
Presentation: Spotlight on medical device MMDR reforms
PDF
This year's highlights and what's ahead for 2017
PPTX
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
PPTX
TGA Presentation: Legislative framework and Commonwealth access schemes relev...
PPTX
Presentation: Updates from the Therapeutic Goods Administration - For medicin...
PDF
Using the new OTC guidance to help compile a successful application
PPTX
Prescription Medicines MMDR Reforms
PPTX
Presentation: Spotlight on prescription medicine post-market reforms
Presentation: GMP clearance requirements for medicines manufactured overseas
Presentation: Spotlight on prescription medicines reforms
Presentation: Prescription Medicines Reforms
TGA presentation: Codeine Industry Forum - Regulatory options for up-scheduling
Presentation: The Australian Pharmacovigilance Inspection Program
Presentation: Pharmacovigilance: The Australian landscape
Presentation: Supply and distribution of therapeutic goods
Presentation: Earlier access to medicines and medical technologies and the MMDR
Updates to Good Manufacturing Practices - Recent, current and future changes
Spotlight on MMDR Further Reviews and Advertising Reforms
Presentation: The Australian Pharmacovigilance Inspection Program (PVIP)
The TGA Pharmacovigilance Inspection Pilot Program: 2015-2016
Presentation: Spotlight on medical device MMDR reforms
This year's highlights and what's ahead for 2017
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...
TGA Presentation: Legislative framework and Commonwealth access schemes relev...
Presentation: Updates from the Therapeutic Goods Administration - For medicin...
Using the new OTC guidance to help compile a successful application
Prescription Medicines MMDR Reforms
Presentation: Spotlight on prescription medicine post-market reforms
Ad

Similar to TGA Presentation: Biologicals framework updates (20)

PDF
TGA presentation: Update on recent activities
PPTX
Update on regulatory reforms from the Scientific Evaluation Branch
PPTX
Update on regulatory reforms from the Scientific Evaluation Branch
PPTX
Regulation of auotologous cell and tissue therapies in Australia
PDF
Presentation Trends in Australian and international regulation and regulatory...
PDF
The regulation of biologicals in Australia
PPTX
Presentation: Regulatory affairs - The Australian and International landscape
PPTX
TGA presentation: AusMedtech, 24 May 2017
PPTX
Medicines and Medical Devices Regulation – current developments and future op...
PDF
Presentation: Regulation of autologous cells and tissues
PDF
Regulation of cell and tissue therapies and clinical research in Australia
PPTX
Changes to the regulation of autologous cells and tissues
PPTX
Siobhan gaynor patientclinicalresearchtalkdec15
PPTX
Module 3 requirements for Biologics (peptide/protein medicines)
PDF
New Directions in Drug Approval in Canada
PPTX
Presentation: Improving the regulation of generic medicines in Australia
PPTX
regulatory requirements of biologicals.pptx
PPTX
The world of Regulatory convergence: an Australian reflection
PDF
RDD 2020 Day 1 PM: Health Canada Regulatory Update
PPTX
TGA presentation: Update on recent activities
Update on regulatory reforms from the Scientific Evaluation Branch
Update on regulatory reforms from the Scientific Evaluation Branch
Regulation of auotologous cell and tissue therapies in Australia
Presentation Trends in Australian and international regulation and regulatory...
The regulation of biologicals in Australia
Presentation: Regulatory affairs - The Australian and International landscape
TGA presentation: AusMedtech, 24 May 2017
Medicines and Medical Devices Regulation – current developments and future op...
Presentation: Regulation of autologous cells and tissues
Regulation of cell and tissue therapies and clinical research in Australia
Changes to the regulation of autologous cells and tissues
Siobhan gaynor patientclinicalresearchtalkdec15
Module 3 requirements for Biologics (peptide/protein medicines)
New Directions in Drug Approval in Canada
Presentation: Improving the regulation of generic medicines in Australia
regulatory requirements of biologicals.pptx
The world of Regulatory convergence: an Australian reflection
RDD 2020 Day 1 PM: Health Canada Regulatory Update
Ad

More from TGA Australia (20)

PPTX
Pharmacovigilance and complementary medicines - Regulatory requirements
PPTX
The challenges of regulating direct to consumer digital medical devices
PPTX
Updates from the Pharmacovigilance and Special Access Branch
PPTX
Consumer Medicine Information - Improving the CMI template
PPTX
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
PPTX
Improved electronic submission methodologies - Challenges and future state
PPTX
Regulation, ethics and reimbursement of novel biological therapies in Austral...
PPTX
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
PPTX
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
PPTX
Reporting of Medicine Shortages
PPTX
Regulatory updates from the TGA Medical Devices Branch - Part 1
PPTX
Regulatory updates from the TGA Medical Devices Branch - Part 2
PPTX
SME Assist: Help to navigate the regulatory maze
PPTX
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
PPTX
Presentation: Updates from the Pharmacovigilance and Special Access Branch
PPTX
Presentation: The challenges of regulating direct to consumer digital medical...
PPTX
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
PPTX
Webinar presentation: Consultation on reforms to the generic medicine market ...
PDF
Presentation: Software as a Medical Device: Regulatory insights and Q & A
PPTX
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...
Pharmacovigilance and complementary medicines - Regulatory requirements
The challenges of regulating direct to consumer digital medical devices
Updates from the Pharmacovigilance and Special Access Branch
Consumer Medicine Information - Improving the CMI template
Regulatory updates from the Complementary and OTC Medicines Branch - Listed m...
Improved electronic submission methodologies - Challenges and future state
Regulation, ethics and reimbursement of novel biological therapies in Austral...
Good Clinical Practice Inspections - Consultation to introduce a pilot progra...
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...
Reporting of Medicine Shortages
Regulatory updates from the TGA Medical Devices Branch - Part 1
Regulatory updates from the TGA Medical Devices Branch - Part 2
SME Assist: Help to navigate the regulatory maze
TGA webinar: The Good Manufacturing Practice (GMP) Clearance Framework – an o...
Presentation: Updates from the Pharmacovigilance and Special Access Branch
Presentation: The challenges of regulating direct to consumer digital medical...
TGA Presentation: Therapeutic Goods Advertising Code (No. 2) 2018
Webinar presentation: Consultation on reforms to the generic medicine market ...
Presentation: Software as a Medical Device: Regulatory insights and Q & A
Presentation: Proposed Reforms to the Regulation of Software, Including Softw...

Recently uploaded (20)

PPTX
1 General Principles of Radiotherapy.pptx
PDF
Medical Evidence in the Criminal Justice Delivery System in.pdf
PPTX
Uterus anatomy embryology, and clinical aspects
PPTX
History and examination of abdomen, & pelvis .pptx
PDF
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
PPTX
neonatal infection(7392992y282939y5.pptx
PPT
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
PPTX
Electromyography (EMG) in Physiotherapy: Principles, Procedure & Clinical App...
PPTX
post stroke aphasia rehabilitation physician
PPTX
Neuropathic pain.ppt treatment managment
PPT
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
PPTX
Respiratory drugs, drugs acting on the respi system
PDF
Rheumatoid arthritis RA_and_the_liver Prof AbdelAzeim Elhefny Ain Shams Univ...
PPTX
Note on Abortion.pptx for the student note
PDF
NEET PG 2025 | 200 High-Yield Recall Topics Across All Subjects
PPTX
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
PPTX
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
DOCX
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
PPTX
ACID BASE management, base deficit correction
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
1 General Principles of Radiotherapy.pptx
Medical Evidence in the Criminal Justice Delivery System in.pdf
Uterus anatomy embryology, and clinical aspects
History and examination of abdomen, & pelvis .pptx
Handout_ NURS 220 Topic 10-Abnormal Pregnancy.pdf
neonatal infection(7392992y282939y5.pptx
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
Electromyography (EMG) in Physiotherapy: Principles, Procedure & Clinical App...
post stroke aphasia rehabilitation physician
Neuropathic pain.ppt treatment managment
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
Respiratory drugs, drugs acting on the respi system
Rheumatoid arthritis RA_and_the_liver Prof AbdelAzeim Elhefny Ain Shams Univ...
Note on Abortion.pptx for the student note
NEET PG 2025 | 200 High-Yield Recall Topics Across All Subjects
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
RUHS II MBBS Microbiology Paper-II with Answer Key | 6th August 2025 (New Sch...
ACID BASE management, base deficit correction
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng

TGA Presentation: Biologicals framework updates

  • 1. Biologicals framework updates Tony Manderson Head, Cell & Tissue Therapies Unit Therapeutic Goods Administration September 2017
  • 2. Overview • Biologicals framework • Current regulatory status • Challenges • Changes – General – Excluded Goods Order – MMDR changes 1
  • 3. Medicines and blood products • prescription medicines • over-the-counter medicines • complementary medicines • blood, blood components and plasma derivatives Medical devices • implants (artificial hips, breast implants) • in-vitro diagnostics (pregnancy tests, blood glucose monitors) • low risk medical devices (bandages, tongue depressors, condoms) Biologicals • human stem cells • tissue-based products (skin and bone) • cell-based products 2
  • 4. What are biologicals? In Australia, ‘biologicals’is the name for cell and tissue therapy products: • Comprises, contains or is derived from human cells or tissues • Represented in any way to be for therapeutic use • Live animal cells, tissues and organs • Framework was introduced on 31 May 2011 to provide a legislative basis for the regulation of these products. • It applies different levels of regulation to products based on the risks associated with their use, and was designed to accommodate emerging technologies. 3
  • 5. The Australian biologicals framework Regulated as biologicals Tissue-based products (skin, bone, ocular, cardiovascular) Cell-based products (T cell therapies, human stem cells) Combined cell and tissue products (collagen matrices for localised cell delivery) Not regulated by TGA* Fresh viable organs Assisted reproductive technologies (in vitro fertilisation) Fresh haematopoietic progenitor cells (bone marrow transplants) Cells and tissues made by a medical practitioner for a single patient under the care of that medical practitioner *It is not practical to regulate these products. There are appropriate checks in place because of professional practice. Regulated, but not as biologicals^ Viable animal tissue products (xenotransplantation) Biological prescription medicines (vaccines, plasma derivatives) Labile blood and blood components Haematopoietic progenitor cells (non-fresh transplants) ^These are regulated as either medicines or medical devices 4 Non-viable animal tissue products 4
  • 6. Biologicals are grouped into classes Examples: Acellular skin for wound covering Mesenchymal stem cell for treatment of graft-versus- host disease Demineralised bone mixed with carrier Dermal fibroblasts transformed for skeletal muscle repair in primary myopathy Genetically- modified T cells used to treat specific virus infections Class 2 Class 3 Class 3 Class 4 Class 4 11
  • 7. Current approvals • Class 2 – All domestic tissue banks (eye, skin, musculoskeletal, cardiovascular) – Some overseas tissue e.g. acellular skin • Class 3 – Ortho-ACI – Demineralised bone matrix - mixed with carrier (overseas) • Class 4 – Approved 4 CTX applications for CAR T cells and parthenogenically- derived stem cells 6
  • 8. Challenges • Clinical trials − Focus on quality aspects that relate to safety e.g. donor selection and testing, control over manufacturing, control of vector, insertional mutagenesis − No review of potency − Control and quality of critical materials • Product registration − Poor product characterisation – defines the design of the manufacturing process − Development of surrogate potency assays − Scale-up, changes to the manufacturing process (comparability) 7
  • 9. Recent and proposed changes • Live animal cell & tissue therapies now under the biologicals framework − Number in clinical trial development e.g. encapsulated porcine islets − Non-living animal tissue still to be regulated as Medical Devices • Update to TGO 75 – Standards for cord blood-derived HPC • Update to TGO 81 – Standards for blood & blood components (2018) • Update to the Australian Regulatory Guidelines for Biologicals − Major structural update to guidance − Revision of content and expansion − Change to dossier structure – CTD • Biovigilance and RMP guidance 8
  • 10. Review of the Therapeutic Goods (Excluded Goods) Order No.1 of 2011 • Autologous cells and tissues (Medical practice) – collected under the care of a medical practitioner, and – manufactured for treatment of a single indication, and – in a single course of treatment of that patient by the same medical practitioner, or by a person under their supervision – Other autologous uses are not exempt in Australia • Under review due to concerns raised by stakeholders • Two rounds of public consultation (2015 & 2016) • Recommendations shortly to be provided to the Minister • Guidance is being prepared • Communication plan 9
  • 11. Medicines and Medical Devices review (MMDR) • Biologicals were not within the scope of the review • Where possible the legislative changes and new pathways will also be rolled out for biologicals • MMDR updates: • Changes to advertising powers and enhanced post-market monitoring capability • Orphan drug program – not for biologicals • Expedited pathways - comparable overseas reports, priority review, provisional approval • Self-assessable notifications, electronic forms for variations • Support and advice for SME’s • SAS C process 10
  • 12. MMDR expedited pathways • To facilitate earlier access to medicines that address unmet clinical needs for Australians, without compromising standards for safety, efficacy and quality. • Two new ‘expedited’ pathways for prescription medicines based on the government response to the recommendations of the MMDR review: – Priority Review of a complete data dossier within a reduced timeframe in certain circumstances Implemented 1 July 2017 – Provisional Approval on the basis of early data on safety and efficacy, where the immediate availability of the medicine outweighs the risk that more data is required Under development, planned for first quarter of 2018 11
  • 13. Expedited pathways: Eligibility criteria • New prescription medicine or new indication • High level eligibility criteria for Priority Review and Provisional Approval  Serious condition; and  Major therapeutic advance; and  Positive comparison against existing therapeutic goods Priority Review based on ‘substantial evidence’ Provisional Approval based on ‘promising evidence from early clinical data’ • Sponsors may apply for the Orphan designation prior to or simultaneously with a Priority Review or Provisional Approval designation application 12
  • 14. Comparable overseas regulator • Expedited review process where a report from a Comparable Overseas Regulator (COR) is available • To replace the current Category 2 process • Consulted on the COR criteria and TGA considerations • The report would be submitted along with a complete dossier, some Australian-specific information and additional evidence, as required. • Further targeted consultation on conditions and proposed pathways to be consulted with industry 13
  • 15. Provisional approval Provisional Approval implementation scheduled for first quarter of 2018 (subject to legislative amendments) • Provisional registration of goods in the initial absence of full clinical data on safety and efficacy • Granted for specified time periods (2 years + up to 2 extensions of 1-2 years each) • Sponsors required to collect and submit further clinical data to demonstrate efficacy and safety for full registration • Enhanced post-market monitoring and surveillance • Subject to the provision of clear advice to consumers and healthcare professionals and any other conditions imposed by the TGA 10
  • 16. Risk-based approach to minor variations - notifications All registered medicines: • OTC • Registered complementary medicines • Prescription (chemical and biological medicines) • Biologicals (human cells and tissues) Staged implementation 15
  • 17. New electronic form for prescription medicines minor variations One-stop shop • Consolidating six PDF forms into one electronic form • Reduced time and effort in making applications • Allows a real-time view of ARTG entries • More efficient processing of requests Launch • 18 sponsors were involved in testing • Progressive soft launch during July • Full launch 25 July 2017 • Paper forms will be turned off as an option by legal instrument in the near future. Prescription Medicines Reforms 16
  • 19. SME Assist Guidance materials should be easily accessed and understood by a range of audiences, including small and medium enterprises (SMEs) • Launched Friday, 9 June 2017 at the Translational Research Institute, Brisbane by the Hon Greg Hunt, Minister for Health and Sport.  Targets the needs of SMEs and R&D groups  Assists them to meet requirements for local and international markets  Provides Australian consumers with earlier access to innovative therapeutic goods
  • 20. SME Assist – 5 key components 1) SME Assist web page  Articles covering basics, market authorisation, when to engage with the TGA  Targeted at SMEs and organisations that have not previously interacted with TGA 2) Education and training  Activities and programs (face-to-face workshops, webinars)  Videos and presentations
  • 21. SME Assist – 5 key components 3) Interactive tools  Decision trees to better understand therapeutic goods regulation relevant to their product − Is my product a therapeutic good? − What classification is my biological? 4) Triage and improved phone/email support  To provide more tailored and efficient assistance to SMEs 5) Improved data capture  To better identify SMEs and sponsors and direct their queries  Subscription list
  • 22. Access to unapproved biologicals Special Access Scheme (SAS) Category C • Certain unapproved therapeutic goods with an established history of use to be supplied • Goods which can be notified under Category C are listed in legislative instruments which specify: − the specific therapeutic good − the approved indication(s) for use and − the health practitioner authorised to supply • Prior approval is not required from • Copy of the completed Category C form must be sent to TGA within 28 days of the therapeutic goods being supplied 21